Načítá se...
MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease
Background: Cushing syndrome is predisposed to hepatocellular disease due to increased visceral fat resulting in NAFLD, and direct effects of medical therapy, notably ketoconazole. Mifepristone (MIFE) (a competitive glucocorticoid receptor antagonist) is a CYP3A4 inhibitor, whereas loestrin (an oral...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551021/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-413 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|